The decision allows Gencor to market Levagen as “ANVISA certified” within Brazil
Gencor has announced the certification of Levagen as a novel food by Brazil’s National Health Surveillance Agency, Agencia Nacional de Vigilancia Sanitaria (ANVISA).
“The ANVISA Novel Food certification opens the Brazilian market for Levagen and strengthens Gencor’s position as an innovator of ingredients that consumers can trust,” said R.V. Venkatesh, Gencor’s MD. “We are very happy to have achieved the certification and will continue to provide ingredients that are well-studied and convey benefits that consumers value.”
ANVISA operates similar to the FDA in the United States, acting as a health regulatory agency for the Brazilian Ministry of Health. The mission of the agency is to protect and promote public health, ensuring the quality and safety of products and services.
Levagen is a clinically studied form of palmitolethanolamide (PEA), which is a fatty acid amide that increases levels of anandamide, an endocannabinoid that regulates pain and sleep receptors. PEA is an endogenous compound that helps to stimulate production of endocannabinoids in the body. PEA can be offset and restored when depleted through dietary supplementation.